Supply of products by Hospira Australia

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply and importation of therapeutic goods in Australia, ensuring their safety, quality, and efficacy. The Act was introduced to address the need for a comprehensive legal framework governing therapeutic goods, including medicines, medical devices, and other related products. Enacted by the Commonwealth Parliament, the policy objective of the Therapeutic Goods Act is to protect public health by ensuring that therapeutic goods available in Australia meet acceptable standards of quality, safety, and efficacy. In a specific case documented in Gazette C2013G01771, the delegate of the Secretary of the Department of Health granted consent for the supply of vancomycin products by Hospira Australia, despite the products not conforming to the letter height requirement specified in Therapeutic Goods Order 69. This consent, subject to certain conditions including a time limit until the end of October 2014 and restrictions on label modifications, underscores the Act's role in balancing regulatory compliance with practical considerations in the therapeutic goods market.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation and control of therapeutic goods in Australia, encompassing a wide range of products such as medicines, medical devices, and blood products. The Act applies to both individuals and entities that manufacture, supply, import, or export therapeutic goods within Australia. Its jurisdiction extends across the Commonwealth, and it is enforced by the Therapeutic Goods Administration (TGA). The Act includes provisions for the establishment of standards and requirements for therapeutic goods, ensuring they are of acceptable quality, safety, and efficacy. In the specific case of the consent given to Hospira Australia, the Act allows for the temporary supply of vancomycin products that do not conform to certain labelling standards, subject to conditions and a limited timeframe, thereby providing flexibility in exceptional circumstances while maintaining overall regulatory oversight. The consent granted by the delegate of the Secretary under the Act is subject to specific conditions, including the limitation that the consent applies only until the end of October 2014 and pertains to the particular foil labels provided by the company in its application. The consent does not extend to any changes in the foil labels or the carton labels, which must remain as currently approved. This demonstrates the Act's capacity to adapt to particular circumstances while enforcing stringent controls to safeguard public health. The Act may also extend its application through subordinate instruments, such as regulations and orders, which provide detailed specifications and requirements that supplement the primary legislative framework.

Key Provisions

The Therapeutic Goods Act 1989 ("the Act") governs the supply of therapeutic goods in Australia, with key sections providing the framework for approvals, consents, and conditions. Section 14 and 14A allow the delegate of the Secretary of the Department of Health to provide consent for the supply of specific therapeutic goods that do not fully comply with certain regulatory standards, such as those outlined in Therapeutic Goods Orders (TGO). This consent is conditional and time-limited, as seen in the consent given to Hospira Australia for the supply of specific vancomycin vials (sections referenced: 14(1), 14A(1)). Under the Act, the obligations imposed on entities like Hospira Australia include ensuring that the products they supply meet the necessary standards or, if not, applying for consent with appropriate justifications. The consent provided in this instance is contingent upon certain conditions, including the duration of the consent, the specific labels involved, and the assurance that no other changes have been made to the approved labels (section 15(1)). It is essential for the company to adhere to these conditions to maintain the validity of the consent and to ensure the safe and compliant supply of therapeutic goods. Failure to comply with the conditions set forth in the consent, or with other requirements of the Act and associated regulations, can result in significant consequences. The Act delineates various offences and associated penalties, which can include both civil and criminal sanctions. For instance, supplying therapeutic goods that do not meet the required standards can lead to substantial fines, imprisonment, or both, depending on the severity and intent behind the breach (section 34(1)). Additionally, repeated or egregious violations can result in more severe penalties, reinforcing the importance of strict adherence to regulatory requirements. The Therapeutic Goods Act 1989 also empowers the delegate to impose further conditions or revoke consent if the conditions are not met or if it is deemed necessary for the protection of public health and safety. This underscores the regulatory framework's focus on ensuring that therapeutic goods supplied in Australia are safe, of high quality, and meet the necessary efficacy standards. The consequences for non-compliance are designed to deter breaches and to encourage compliance with the stringent regulatory environment governing therapeutic goods.